BioCentury
ARTICLE | Company News

Nicox, Trinity, Sjogren's Syndrome Foundation sales and marketing update

November 25, 2013 8:00 AM UTC

Nicox launched the Sjo diagnostic panel from Immco Diagnostics Inc., now part of Trinity, in the U.S. to detect Sjogren's syndrome. The test, which FDA approved earlier this year, has a list price of $572 and uses salivary gland protein 1 (SP-1), carbonic anhydrase VI (CAVI), parotid secretory protein (PSP), anti-nuclear antibody (ANA), Ro and La antibodies and rheumatoid factor (RF) biomarkers. In June, Immco granted Nicox exclusive rights to commercialize Sjo in North America and a nine-month option to negotiate an agreement to promote the test in the rest of the world. Nicox said a decision on exercising the option has not yet been reached. Under the deal, revenues will be shared and Nicox will receive a "majority" share of Sjo revenues. The test is also available in Canada, Puerto Rico and Mexico. Trinity acquired Immco in July for $32.8 million. The companies could not be reached for details (see BioCentury, June 24)...